Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Pt-141 is a synthetic peptide used to largely treat sexual dysfunction in women
Evidence Summary: What the Data Suggest Several phase 2 and observational studies highlight the hepatic benefits of GLP1based treatment: Reduced liver fat: Repeated findings in imaging-based studies support this effect Lower liver enzymes: Consistent reductions in ALT/AST levels Fibrosis improvement: Promising trends in noninvasive markers, though further trials are needed While the strongest evidence comes from patients with obesity or type 2 diabetes, benefits in leaner, metabolically abnormal patients are increasingly documented, suggesting broader utility
doi: 10.7554/eLife.50631CrossRefGoogle ScholarPubMed Chiu, K
Egbert JR, Fahey PG, Reimer J, Owen CM, Evsikov AV, Nikolaev VO, et al
In November 2023, Eccogene entered into a global licensing agreement with AstraZeneca for elecoglipron while retaining co-development and co-commercialization rights in China
US$ 21.00
US$ 25.51
US$ 20.97
US$ 21.46
US$ 23.97
US$ 20.96
US$ 25.16
US$ 27.45
